Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed with melanoma based on International Classification of Disease 9th and 10th Revisions (ICD-9: 172.x; ICD-10: C43x, D03x) and ≥2 visits on different days in the Flatiron database on or after January 1, 2011.
Clinically confirmed diagnosis of melanoma with pathologic stages III or IV at initial diagnosis or earlier stage disease with a first locoregional or distant recurrence on or after January 1, 2011.
Age ≥18 years at the time of advanced melanoma diagnosis.
Evidence of ≥1 BRAF positive test result at any time based on laboratory or genetic analysis results.
You may not be if
• Patients with prior BRAF- or MEK-inhibitor therapy
Patients with ECOG performance status ≥ 2 (at the time of randomization for patients from COLUMBUS, during the baseline period for patients in Flatiron EHR)
Clareo Health | Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US
